vs
自然阳光（NATR）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是自然阳光的1.2倍（$151.1M vs $123.8M），自然阳光同比增速更快（4.7% vs 3.6%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $7.6M），过去两年自然阳光的营收复合增速更高（5.6% vs 5.1%）
自然阳光产品公司（简称NSP）主营膳食补充剂与个人护理产品的生产制造，产品涵盖草本补充剂、维生素、矿物质制剂等品类。公司总部设于犹他州利希，生产工厂位于犹他州西班牙福克，是该领域知名的健康产品生产商。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
NATR vs RGR — 直观对比
营收规模更大
RGR
是对方的1.2倍
$123.8M
营收增速更快
NATR
高出1.1%
3.6%
自由现金流更多
RGR
多$4.8M
$7.6M
两年增速更快
NATR
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $123.8M | $151.1M |
| 净利润 | $4.1M | — |
| 毛利率 | 72.5% | 17.8% |
| 营业利润率 | 4.3% | 2.3% |
| 净利率 | 3.3% | — |
| 营收同比 | 4.7% | 3.6% |
| 净利润同比 | 1379.4% | — |
| 每股收益（稀释后） | $0.23 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NATRRGR
| Q4 25 | $123.8M | $151.1M | ||
| Q3 25 | $128.3M | $126.8M | ||
| Q2 25 | $114.8M | $132.5M | ||
| Q1 25 | $113.2M | $135.7M | ||
| Q4 24 | $118.2M | $145.8M | ||
| Q3 24 | $114.6M | $122.3M | ||
| Q2 24 | $110.6M | $130.8M | ||
| Q1 24 | $111.0M | $136.8M |
净利润NATRRGR
| Q4 25 | $4.1M | — | ||
| Q3 25 | $5.3M | $1.6M | ||
| Q2 25 | $5.3M | $-17.2M | ||
| Q1 25 | $4.7M | $7.8M | ||
| Q4 24 | $-321.0K | — | ||
| Q3 24 | $4.3M | $4.7M | ||
| Q2 24 | $1.3M | $8.3M | ||
| Q1 24 | $2.3M | $7.1M |
毛利率NATRRGR
| Q4 25 | 72.5% | 17.8% | ||
| Q3 25 | 73.3% | 15.1% | ||
| Q2 25 | 71.7% | 3.9% | ||
| Q1 25 | 72.1% | 22.0% | ||
| Q4 24 | 72.0% | 22.8% | ||
| Q3 24 | 71.3% | 18.5% | ||
| Q2 24 | 71.4% | 22.3% | ||
| Q1 24 | 71.2% | 21.5% |
营业利润率NATRRGR
| Q4 25 | 4.3% | 2.3% | ||
| Q3 25 | 7.0% | -2.7% | ||
| Q2 25 | 3.7% | -15.6% | ||
| Q1 25 | 5.4% | 6.2% | ||
| Q4 24 | 3.8% | 7.8% | ||
| Q3 24 | 4.6% | 3.1% | ||
| Q2 24 | 5.1% | 6.9% | ||
| Q1 24 | 4.2% | 5.5% |
净利率NATRRGR
| Q4 25 | 3.3% | — | ||
| Q3 25 | 4.2% | 1.2% | ||
| Q2 25 | 4.6% | -13.0% | ||
| Q1 25 | 4.2% | 5.7% | ||
| Q4 24 | -0.3% | — | ||
| Q3 24 | 3.8% | 3.9% | ||
| Q2 24 | 1.2% | 6.3% | ||
| Q1 24 | 2.1% | 5.2% |
每股收益（稀释后）NATRRGR
| Q4 25 | $0.23 | $0.22 | ||
| Q3 25 | $0.30 | $0.10 | ||
| Q2 25 | $0.28 | $-1.05 | ||
| Q1 25 | $0.25 | $0.46 | ||
| Q4 24 | $-0.02 | $0.62 | ||
| Q3 24 | $0.23 | $0.28 | ||
| Q2 24 | $0.07 | $0.47 | ||
| Q1 24 | $0.12 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.9M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $161.6M | $283.8M |
| 总资产 | $261.1M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NATRRGR
| Q4 25 | $93.9M | $92.5M | ||
| Q3 25 | $95.6M | $80.8M | ||
| Q2 25 | $81.3M | $101.4M | ||
| Q1 25 | $86.5M | $108.3M | ||
| Q4 24 | $84.7M | $105.5M | ||
| Q3 24 | $78.7M | $96.0M | ||
| Q2 24 | $68.7M | $105.6M | ||
| Q1 24 | $77.8M | $115.3M |
总债务NATRRGR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
股东权益NATRRGR
| Q4 25 | $161.6M | $283.8M | ||
| Q3 25 | $166.7M | $279.6M | ||
| Q2 25 | $163.7M | $289.3M | ||
| Q1 25 | $167.1M | $321.5M | ||
| Q4 24 | $161.0M | $319.6M | ||
| Q3 24 | $162.6M | $314.9M | ||
| Q2 24 | $156.4M | $321.5M | ||
| Q1 24 | $159.7M | $332.0M |
总资产NATRRGR
| Q4 25 | $261.1M | $342.0M | ||
| Q3 25 | $264.8M | $342.3M | ||
| Q2 25 | $254.9M | $349.5M | ||
| Q1 25 | $252.7M | $379.0M | ||
| Q4 24 | $240.9M | $384.0M | ||
| Q3 24 | $245.3M | $373.5M | ||
| Q2 24 | $235.8M | $376.7M | ||
| Q1 24 | $247.3M | $385.0M |
负债/权益比NATRRGR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $7.6M | $12.3M |
| 自由现金流率自由现金流/营收 | 6.1% | 8.2% |
| 资本支出强度资本支出/营收 | 1.9% | 2.1% |
| 现金转化率经营现金流/净利润 | 2.41× | — |
| 过去12个月自由现金流最近4个季度 | $28.8M | $38.5M |
8季度趋势，按日历期对齐
经营现金流NATRRGR
| Q4 25 | $9.9M | $15.5M | ||
| Q3 25 | $18.5M | $12.9M | ||
| Q2 25 | $4.3M | $14.7M | ||
| Q1 25 | $2.6M | $11.1M | ||
| Q4 24 | $12.2M | $20.0M | ||
| Q3 24 | $9.6M | $9.4M | ||
| Q2 24 | $1.3M | $18.7M | ||
| Q1 24 | $2.2M | $7.3M |
自由现金流NATRRGR
| Q4 25 | $7.6M | $12.3M | ||
| Q3 25 | $16.8M | $7.0M | ||
| Q2 25 | $3.0M | $9.1M | ||
| Q1 25 | $1.5M | $10.0M | ||
| Q4 24 | $10.0M | $16.4M | ||
| Q3 24 | $7.9M | $2.6M | ||
| Q2 24 | $-2.0M | $10.1M | ||
| Q1 24 | $-1.5M | $5.6M |
自由现金流率NATRRGR
| Q4 25 | 6.1% | 8.2% | ||
| Q3 25 | 13.1% | 5.5% | ||
| Q2 25 | 2.6% | 6.9% | ||
| Q1 25 | 1.3% | 7.4% | ||
| Q4 24 | 8.5% | 11.2% | ||
| Q3 24 | 6.9% | 2.1% | ||
| Q2 24 | -1.9% | 7.7% | ||
| Q1 24 | -1.4% | 4.1% |
资本支出强度NATRRGR
| Q4 25 | 1.9% | 2.1% | ||
| Q3 25 | 1.3% | 4.6% | ||
| Q2 25 | 1.2% | 4.2% | ||
| Q1 25 | 1.0% | 0.8% | ||
| Q4 24 | 1.9% | 2.5% | ||
| Q3 24 | 1.5% | 5.5% | ||
| Q2 24 | 3.0% | 6.6% | ||
| Q1 24 | 3.3% | 1.3% |
现金转化率NATRRGR
| Q4 25 | 2.41× | — | ||
| Q3 25 | 3.46× | 8.15× | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | 1.98× | ||
| Q2 24 | 0.97× | 2.27× | ||
| Q1 24 | 0.94× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
